Meeting
2020 ASCO Virtual Scientific Program
Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Authors
Shaji Kumar
Mayo Clinic, Rochester, MN
Shaji Kumar , Simon J. Harrison , Michele Cavo , Javier de La Rubia , Rakesh Popat , Cristina Gasparetto , Vania Hungria , Hans Salwender , Kenshi Suzuki , Inho Kim , Francesca Gay , Gabor Mikala , Elizabeth Punnoose , Wan-Jen Hong , Anjla Sood , Muhammad Jalaluddin , Jeremy A. Ross , James M Pauff , Paulo Cesar Maciag , Philippe Moreau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT02755597
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8509)
DOI
10.1200/JCO.2020.38.15_suppl.8509
Abstract #
8509
Poster Bd #
409
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.
First Author: Philippe Moreau
Poster
2020 ASCO Virtual Scientific Program
Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.
First Author: Jonathan L. Kaufman
Poster
2015 ASCO Annual Meeting
![MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).](https://d201v5jt9ylckg.cloudfront.net/156/9331/115230/115230_poster_pv.jpg)
MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).
First Author: Paul G. Richardson
Poster
2013 ASCO Annual Meeting
Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).
First Author: Katja C. Weisel